Minimal Residual Disease is defined as the small number of cancer cells that can remain in the body during or after treatment. These residual cells are often not detectable by conventional testing methods and can lead to disease relapse in the future. This makes MRD an important consideration in the management of [...]
Introduction In this article, we introduce mass spectrometry testing as a new and promising technology for blood-based MRD in multiple myeloma. We will discuss the two different mass spectrometry methods currently available and highlight their benefits and limitations. Multiple myeloma is a plasma cell disorder caused by the buildup of myeloma cells [...]
Introduction In this article, we revisit the M-spike protein and its importance as a biomarker in multiple myeloma. The introduction and use of novel and powerful treatment options have significantly improved the outcomes for multiple myeloma patients. With response rates close to 100%, clinicians are looking for better tools for monitoring minimal [...]